Investor's Business Daily on MSN
Abivax hits 'best-case' scenario for ulcerative colitis drug; so, why did shares plummet?
Abivax stock plummeted Tuesday after several patients developed cancer following a study of its ulcerative colitis treatment.
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but ...
InvestorsHub on MSN
Abivax shares tumble despite strong ulcerative colitis trial results as safety concerns emerge (ABVX)
Abivax (NASDAQ:ABVX) shares fell sharply on Tuesday after investors focused on reports of rare malignancy cases in a ...
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as ...
Abivax ABVX ulcerative colitis phase 3 win, but rare cancers keep a Hold ahead of the Q4 2026 NDA. Click here to read my most ...
The company dismissed the cancers observed in the trial as rare, occurring primarily in older patients, and largely unrelated to treatment.
A combination of two medications may offer better results in treating inflammatory bowel disease (IBD) than using each drug ...
IBD is a chronic disorder that requires regular treatment and a healthy lifestyle to keep in check. However, some mistakes are commonly made, explains Dr Sethi.
Inflammatory bowel disease (IBD) flares can be unpredictable, but avoiding common triggers like stress, poor sleep, smoking, and certain dietary factors may help lower your risk of future flare-ups.
Experts offer treatment tips for patients with axial spondyloarthritis who also have inflammatory bowel disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results